Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Cut to $139.00 by Analysts at Bank of America

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price lowered by Bank of America from $145.00 to $139.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Rhythm Pharmaceuticals in a report on Friday, December 12th. Wells Fargo & Company boosted their price objective on Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Morgan Stanley cut their target price on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a research note on Tuesday. Stifel Nicolaus set a $131.00 target price on Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Finally, Canaccord Genuity Group decreased their price target on shares of Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating on the stock in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $131.75.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $87.68 on Tuesday. The firm’s 50-day moving average is $99.77 and its 200-day moving average is $102.81. The company has a market cap of $5.99 billion, a price-to-earnings ratio of -28.19 and a beta of 2.06. Rhythm Pharmaceuticals has a 52-week low of $45.90 and a 52-week high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business had revenue of $57.25 million during the quarter, compared to analysts’ expectations of $56.16 million. During the same quarter last year, the company earned ($0.72) earnings per share. The firm’s revenue was up 36.9% on a year-over-year basis. Equities analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer directly owned 160 shares of the company’s stock, valued at $14,329.60. This represents a 97.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 27,267 shares of company stock valued at $2,719,955. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its stake in Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after purchasing an additional 145 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares in the last quarter.

More Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company delivered solid revenue growth and a Q4 beat (FY25 revenue $194.8M, +50% year/year), which supports continued commercial demand for IMCIVREE (setmelanotide) and underpins longer-term upside. Article Title
• Positive Sentiment: Company highlights post‑hoc analyses showing statistically significant BMI reductions at 52 weeks in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants — these subgroup signals could support label expansion or targeted use, which investors may view as constructive if regulators/market accept the evidence. Article Title
• Neutral Sentiment: Company-hosted transcript and slide materials on the EMANATE topline results are available for investors evaluating the detailed data and management commentary; these provide context for both the misses and the subgroup findings. Transcript Slides
• Negative Sentiment: Topline EMANATE results showed the experimental obesity program did not meet several pre‑specified primary endpoints across four substudies — the primary failure is the main driver of near‑term negative sentiment and regulatory scrutiny. Reuters
• Negative Sentiment: Multiple major brokerages trimmed price targets today (Citigroup, RBC, Citizens JMP, BofA, Morgan Stanley, Needham). Although most retained buy/outperform ratings, the lower targets signal reduced near‑term upside expectations and likely contributed to selling pressure. Benzinga TickerReport

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.